Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Completed Cohort Consortium Projects

These are Cohort Consortium-approved projects that have been completed or closed and are therefore no longer active. For more information please contact the investigator(s).

A pooled investigation of circulating adiponectin and multiple myeloma

African American Working Group

Project Status:

Completed Project (Historical)

Investigator(s):

Julie R. Palmer (jpalmer@bu.edu), William J. Blot (william.j.blot@Vanderbilt.Edu), Nonye Harvey (harveyn@mail.nih.gov), and others

Year Initiated:

2011

Project Background:

The African American Working Group of the NCI Cohort Consortium was formed in 2011 when seven large epidemiology cohorts, each with at least 10,000 African American participants, joined to look at anthropometric measures in relation to mortality in African Americans. The original goals of the Working Group were to assess the relation of body mass index to all-cause, cancer, and CVD mortality, and then pancreas cancer and multiple myeloma, in African American men and women. Limited NCI extramural funds supported data harmonization and preparation of analysis datasets. Since then the Working Group's objectives have expanded to broadly examine determinants of cancer risk and outcome among African Americans. The group now provides a platform for development of new collaborative research leveraging existing data and resources in the Cohort Consortium. The seven cohorts participating in this project are: NIH-AARP; Adventist Health Study 2; Black Women's Health Study; Cancer Prevention Study II; Multiethnic Cohort Study; Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; and Southern Community Cohort Study

Related Publications:

Multiple Myeloma Mortality in Relation to Obesity Among African Americans. (2016)

A pooled analysis of body mass index and pancreatic cancer mortality in african americans. (2014)

A pooled analysis of body mass index and mortality among African Americans. (2014)

Aspirin, non-aspirin NSAID, acetaminophen use and ovarian cancer risk

BMI and Mortality in Asian Americans

Project Status:

Completed Project (Historical)

Investigator(s):

Yikyung Park (yikyung.park@nih.gov), Sophia Wang (sowang@coh.org), Walter Willett (walter.willett@channing.harvard.edu), and others

Year Initiated:

2011

Project Background:

This project evaluated the association between BMI and mortality in 20,672 Asian Americans by pooling data from 10 prospective cohort studies. Results were published in 2014.

BMI and Multiple Myeloma Mortality

Project Status:

Completed Project (Historical)

Investigator(s):

Lauren Teras (lauren.teras@cancer.org), Cari Kitahara (kitaharac@mail.nih.gov), Mark Purdue (purduem@mail.nih.gov), and others

Year Initiated:

2012

Project Background:

This project evaluated the relationship between anthropometric measures (e.g., height, baseline BMI, young-adult BMI, BMI change, waist/hip ratio) and death from multiple myeloma by pooling data from 20 prospective cohort studies, including 1.5 million study participants. Results were published in 2014.

Related Publications:

Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. (2014)

BMI, Body Fat Distribution, and Mortality

Project Status:

Completed Project (Historical)

Investigator(s):

James Cerhan (cerhan.james@mayo.edu), Patricia Hartge (hartgep@mail.nih.gov), Leslie Bernstein (lbernstein@coh.org), and Amy Berrington de Gonzalez (berringtona@mail.nih.gov) for the BMI Cohort Consortium

Year Initiated:

2011

Project Background:

This project began in 2011 to assess the association of waist circumference with total and selected cause-specific (e.g., cardiovascular, cancer) mortality. A secondary analysis assessed hip circumference and waist-to-hip ratio, using data on more than 650,000 participants from 11 cohorts in the BMI and Mortality and Physical Activity Pooling Projects. The project has been completed and a manuscript is being submitted to a peer reviewed journal.

Related Publications:

A pooled analysis of waist circumference and mortality in 650,000 adults. (2014)

Biomarkers and Breast Cancer Risk Prediction in Younger Women

Project Status:

Completed Project (Historical)

Investigator(s):

Anne Zeleniuch-Jacquotte (anne.jacquotte@nyumc.org)

Year Initiated:

2012

Project Background:

This study, initiated in 2012, is developing an improved breast cancer risk prediction model for premenopausal women under 50 years of age. The model could have applications for both screening and chemoprevention. The study is assessing whether adding biomarkers (i.e., testosterone, free testosterone, circulating Müllerian Inhibiting Substance [MIS]) to the Breast Cancer Risk Assessment Tool (also known as the Gail Model) improves risk prediction in women under 50. The results could help younger women decide: (1) the most appropriate age to begin screening, and (2) whether to take tamoxifen for chemoprevention.


Related Publications:

Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. (2019)

Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. (2018)

Body Mass Index (BMI) All-Cause Mortality Pooling Project

Project Status:

Completed Project (Historical)

Investigator(s):

Amy Berrington de Gonzalez (berringtona@mail.nih.gov), Michael Thun (michael.thun@cancer.org), and others

Year Initiated:

2007

Project Background:

This project began in 2007 as a collaborative effort among more than 20 prospective epidemiologic studies to examine and quantify the relationship between BMI and all-cause mortality; and determine the extent to which the relationship between BMI and all-cause mortality varies by factors such as age, sex, smoking status, preexisting heart disease or cancer, physical activity, alcohol intake, education, and marital status. The project analyzed pooled data from prospective studies encompassing 1.46 million adults to estimate hazard ratios for the association between BMI and all-cause mortality. The results were published in 2010. For more information, please visit: https://epi.grants.cancer.gov/bmi-pooling-project/

Related Publications:

Body mass index and risk of death in Asian Americans. (2014)

Body-mass index and mortality among 1.46 million white adults. (2010)

Breast and Prostate Cancer Cohort Consortium (BPC3) (Phase I)

Project Status:

Completed Project (Historical)

Investigator(s):

David Hunter (david.hunter@channing.harvard.edu), Michael Thun (michael.thun@cancer.org), Elio Riboli (e.riboli@imperial.ac.uk), and Brian Henderson

Year Initiated:

2003

Project Background:

The BPC3 began in 2003 to study hormone-related gene variants and environmental factors involved in the development of breast and prostate cancers. The goal was to characterize variations in about 55 candidate genes that mediate the steroid hormone metabolism and insulin-like growth factor (IGF) signaling pathways, and associate these variations with cancer risk. In 2007, the BPC3 expanded the study population and used a genome-wide association approach to identify genetic variants that may be associated with estrogen receptor negative breast cancer, as well as aggressive forms of prostate cancer. For more information, please visit: https://epi.grants.cancer.gov/bpc3/

Related Publications:

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. (2016)

Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. (2016)

Association of breast cancer risk loci with breast cancer survival. (2015)

ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). (2015)

Genome-wide association study of prostate cancer-specific survival. (2015)

Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2015)

Genetic risk variants associated with in situ breast cancer. (2015)

A genome-wide pleiotropy scan for prostate cancer risk. (2015)

Vitamin D-associated genetic variation and risk of breast cancer in the breast and prostate cancer cohort consortium (BPC3). (2015)

Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. (2014)

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. (2014)

Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. (2014)

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. (2014)

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2014)

Factors associated with oxidative stress and cancer risk in the Breast and Prostate Cancer Cohort Consortium. (2014)

A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. (2014)

Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2013)

One thousand genomes imputation in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium aggressive prostate cancer genome-wide association study. (2013)

Plasma carotenoid- and retinol-weighted multi-SNP scores and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2013)

Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium. (2013)

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. (2013)

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013)

Re-ranking sequencing variants in the post-GWAS era for accurate causal variant identification. (2013)

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012)

Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. (2012)

Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. (2012)

Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2012)

Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2012)

Informed conditioning on clinical covariates increases power in case-control association studies. (2012)

Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2012)

N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in the breast and prostate cancer cohort consortium. (2011)

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. (2011)

Genome-wide association study identifies new prostate cancer susceptibility loci. (2011)

Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. (2011)

Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. (2011)

Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). (2011)

Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. (2010)

Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. (2010)

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2010)

A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. (2010)

Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. (2010)

Performance of common genetic variants in breast-cancer risk models. (2010)

Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. (2010)

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). (2010)

Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. (2010)

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. (2009)

Identification of a new prostate cancer susceptibility locus on chromosome 8q24. (2009)

Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). (2009)

Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2009)

Complex diseases, complex genes: keeping pathways on the right track. (2009)

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). (2009)

Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2009)

Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. (2008)

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). (2008)

Multiple loci identified in a genome-wide association study of prostate cancer. (2008)

Haplotypes of the estrogen receptor beta gene and breast cancer risk. (2008)

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2007)

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2007)

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. (2007)

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. (2007)

A common 8q24 variant in prostate and breast cancer from a large nested case-control study. (2007)

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. (2007)

Exploiting gene-environment interaction to detect genetic associations. (2007)

Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. (2006)

A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2006)

A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. (2005)

Genetic variation in the HSD17B1 gene and risk of prostate cancer. (2005)

Breast and Prostate Cancer Cohort Consortium (BPC3) (Phase II)

Project Status:

Completed Project (Historical)

Investigator(s):

Susan Gapstur (susan.gapstur@cancer.org), Stephen Chanock (chanocks@mail.nih.gov), Mia Gaudet (mia.gaudet@cancer.org), Peter Kraft (pkraft@hsph.harvard.edu) and others

Year Initiated:

2007

Project Background:

This new BPC3 study will expand the first phase of BPC3 to serve as a rapid verification test set for SNPs identified in the scans other than the CGEMS scan, and to examine gene-environment interactions in the SNPs identified in CGEMS and other studies as being associated with breast and prostate cancer. With the completion of GWAS for breast cancer and prostate cancers in aggregate, important questions remain that the BPC3 is uniquely positioned to answer. Estrogen receptor negative (ER-) breast cancers have specific epidemiologic characteristics and greater lethality, but the current generation of scans is underpowered to discover gene variants associated with these tumors. Aggressive forms of prostate cancer, characterized by extraprostatic extension (Stage C/D) or high histologic grade (Gleason score 8+), differ epidemiologically from the vastly more common indolent forms of prostate cancer and are of the greatest clinical importance, but again the current scans are underpowered to discover associated genetic determinants. No single study is likely to have enough cases of these cancer subtypes to perform a GWAS. By pooling cases across the BPC3 studies, the investigators can achieve adequate power to discover genetic variation that gives rise to these important clinical subtypes. For more information, please visit: https://epi.grants.cancer.gov/bpc3/abstract2.html

Related Documents:


Related Publications:

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. (2016)

Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. (2016)

Association of breast cancer risk loci with breast cancer survival. (2015)

ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). (2015)

Genome-wide association study of prostate cancer-specific survival. (2015)

Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2015)

Genetic risk variants associated with in situ breast cancer. (2015)

A genome-wide pleiotropy scan for prostate cancer risk. (2015)

Vitamin D-associated genetic variation and risk of breast cancer in the breast and prostate cancer cohort consortium (BPC3). (2015)

Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. (2014)

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. (2014)

Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. (2014)

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. (2014)

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2014)

Factors associated with oxidative stress and cancer risk in the Breast and Prostate Cancer Cohort Consortium. (2014)

A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. (2014)

Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2013)

One thousand genomes imputation in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium aggressive prostate cancer genome-wide association study. (2013)

Plasma carotenoid- and retinol-weighted multi-SNP scores and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2013)

Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium. (2013)

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. (2013)

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013)

Re-ranking sequencing variants in the post-GWAS era for accurate causal variant identification. (2013)

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012)

Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. (2012)

Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. (2012)

Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2012)

Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2012)

Informed conditioning on clinical covariates increases power in case-control association studies. (2012)

Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). (2012)

N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in the breast and prostate cancer cohort consortium. (2011)

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. (2011)

Genome-wide association study identifies new prostate cancer susceptibility loci. (2011)

Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. (2011)

Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. (2011)

Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). (2011)

Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. (2010)

Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. (2010)

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2010)

A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. (2010)

Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. (2010)

Performance of common genetic variants in breast-cancer risk models. (2010)

Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. (2010)

PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). (2010)

Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. (2010)

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. (2009)

Identification of a new prostate cancer susceptibility locus on chromosome 8q24. (2009)

Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). (2009)

Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2009)

Complex diseases, complex genes: keeping pathways on the right track. (2009)

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). (2009)

Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2009)

Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. (2008)

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). (2008)

Multiple loci identified in a genome-wide association study of prostate cancer. (2008)

Haplotypes of the estrogen receptor beta gene and breast cancer risk. (2008)

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2007)

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2007)

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. (2007)

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. (2007)

A common 8q24 variant in prostate and breast cancer from a large nested case-control study. (2007)

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. (2007)

Exploiting gene-environment interaction to detect genetic associations. (2007)

Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. (2006)

A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). (2006)

A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. (2005)

Genetic variation in the HSD17B1 gene and risk of prostate cancer. (2005)

Class III Obesity and Mortality

Project Status:

Completed Project (Historical)

Investigator(s):

Cari Kitahara (kitaharac@mail.nih.gov), Patricia Hartge (hartgep@mail.nih.gov), Amy Berrington de Gonzalez (berringtona@mail.nih.gov), and others

Year Initiated:

2014

Project Background:

This pooled analysis of 20 prospective cohort studies evaluated total and cause-specific mortality rates for adults with BMI values in the class III obesity range (BMI 40-59) compared with those classified as normal-weight (BMI 18.5-24.9). Study participants included 9,564 adults in the class III obesity group and 304,011 adults in the normal-weight group, all of whom were never smokers and without a history of heart disease, cancer, stroke, or emphysema at study entry. Results were published in 2014.

Related Publications:

Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. (2014)

Cohort Consortium Tissue Project Group

Project Status:

Completed Project (Historical)

Investigator(s):

Mia Gaudet (mia.gaudet@cancer.org), Lorelie Mucci (lmucci@hsph.harvard.edu), and Danielle Carrick(Danielle.Carrick@nih.gov)

Year Initiated:

2014

Project Background:

The Cohort Consortium Tissue Working Group was formed in the summer of 2014 to create a community of investigators interested in integrating tissue biomarkers into epidemiological studies. The goals of the working group are: 1. Share lessons learned regarding the acquisition of tumor tissue within cohort studies, 2. Allow other cohorts to learn from experienced cohorts in acquisition of tissue, 3. Develop best practices and technical guidance regarding tissue for cohort studies, 4. Discuss the application of technologies and assays – mRNA profiling, methylation, microRNA, immunohistochemistry, etc – and its use in the archival materials, and 5. Provide a forum for future collaborative work. Webinars are scheduled approximately every 3 months. Please contact Danielle Carrick if you would like to be added to the working group.

Cohort-based GWAS of Glioma (GliomaScan)

Project Status:

Completed Project (Historical)

Investigator(s):

Martha Linet (linetm@mail.nih.gov), Preetha Rajaraman (rajarama@mail.nih.gov) and Beatrice Melin (beatrice.melin@onkologi.umu.se)

Year Initiated:

2008

Project Background:

GliomaScan, begun in 2008, investigates the etiology, prevention, and treatment of brain tumors by conducting a GWAS study of glioma with a large number of cohort-derived samples. Follow-up analyses are examining genetic pathways, gene-gene, and gene-environment interactions. The study has found evidence of strong replication for three previously reported associations; larger studies focusing on novel approaches as well as specific tumor subtypes or subgroups will be required to identify additional common susceptibility loci for glioma risk.

Related Publications:

Known glioma risk loci are associated with glioma with a family history of brain tumours -- a case-control gene association study. (2013)

Genome-wide association study of glioma and meta-analysis. (2012)

Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. (2012)

Association between adult height, genetic susceptibility and risk of glioma. (2012)

A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. (2012)

DNA Methylation Biomarkers of Primary Liver Cancer Risk

Diet/Activity Assessment Methods Project

Project Status:

Completed Project (Historical)

Investigator(s):

Yikyung Park (parky@wudosis.wustl.edu) and Amy Subar (subara@mail.nih.gov)

Year Initiated:

2008

Project Background:

The Diet/Activity Assessment Methods Project, initiated in 2008, evaluates the measurement error structure of several self-reported, Internet-based, diet and physical activity assessment tools and questionnaires (e.g., food frequency and physical activity) and compares them against reference biomarkers and activity monitors among participants in the NIH-AARP Diet and Health Study, Harvard's Nurses' Health Study, and Health Professionals Follow-up Study.

Gastric and Esophageal Squamous Cell Carcinomas GWAS

Project Status:

Completed Project (Historical)

Investigator(s):

Christian Abnet (abnetc@mail.nih.gov), Alicja Wolk (Alicja.Wolk@ki.se), and others

Year Initiated:

2008

Project Background:

This study, initiated in 2008, is conducting a GWAS in two anatomically different upper gastrointestinal cancer sites in two populations with distinctly different disease rates and genetic profiles. One population has very high rates of both esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC) and consists of participants from East Asian countries. The other population has low rates of ESCC and GC and includes participants from the Americas, Europe, Australia, the Middle East, and others.

Related Publications:

Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. (2014)

Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. (2012)

Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. (2012)

Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. (2011)

Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)

Genome-Wide Association Study of Endometrial Cancer

Project Status:

Completed Project (Historical)

Investigator(s):

Immaculata De Vivo (devivo@channing.harvard.edu) and others

Year Initiated:

2008

Project Background:

Begun in 2008, this project is identifying the genes involved in endometrial cancer to help identify novel targets for endometrial cancer risk prediction, prevention, and treatment. The researchers are genotyping more than 2,600 Type I endometrial cancer cases of European descent and an equal number of controls. The effect of the SNPs that indicate genome-wide significance will be characterized in terms of body mass index, exogenous hormone use, and other established endometrial cancer risk factors. This project has been completed and a manuscript is currently under review.

Related Publications:

GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. (2016)

Symposium on advances in endometrial cancer epidemiology and biology. (2015)

Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). (2015)

Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. (2015)

Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). (2015)

Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. (2015)

Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. (2014)

Genome-wide association study of endometrial cancer in E2C2. (2014)

Exome-wide association study of endometrial cancer in a multiethnic population. (2014)

Type I and II endometrial cancers: have they different risk factors? (2013)

The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. (2013)

Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. (2012)

The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. (2011)

Maximizing resources to study an uncommon cancer: E2C2--Epidemiology of Endometrial Cancer Consortium. (2009)

Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. (2009)

Genomic Determinants of Serum Vitamin D

Project Status:

Completed Project (Historical)

Investigator(s):

Demetrius Albanes (albanesd@mail.nih.gov)

Year Initiated:

2008

Project Background:

Prostate cancer is the most common malignancy in men in most developed populations, and few modifiable etiological factors have been established. Substantial recent interest in the potential health benefits of several micronutrients and vitamin supplements, including 25-hydroxy-vitamin D (25(OH)D), tocopherols (vitamin E), and retinol (vitamin A), has raised attention with respect to available human evidence for their relationships to cancer, including prostate cancer. With respect to vitamin D, for example, the Cohort Consortium Vitamin D Pooling Project (VDPP) provided no evidence to support a beneficial association with rarer cancers, but did suggest increased pancreatic cancer risk for persons with the highest 25(OH)D concentrations. Studies of breast and colorectal cancer are ongoing, including within the Cohort Consortium through a recently awarded NCI grant. With respect to prostate cancer, a recent literature review-based meta-analysis of nested case-control studies of 25(OH)D concluded there was no beneficial association for higher vitamin D status, and that a weak causal relation was possible. Findings for aggressive cancers have been limited and less conclusive. By contrast, most basic research supports a beneficial role for vitamin D compounds in prostate cell proliferation and differentiation, prostate cancer cell growth and invasion, and tumorigenesis, and ecologic data suggest correlations between prostate (and other organ site) cancer rates and latitude. Given the clinical significance of prostate cancer, a more definitive understanding is needed of the potential impact vitamin D status may have on its occurrence and outcome. Vitamin E and the tocopherols have been extensively studied and shown potential promise with respect to prostate cancer prevention, yet the results from controlled trials such as the ATBC Study, SELECT, and PHS-II, as well as nested observational serologic studies, raise the issue of a preventive influence being confined to cigarette smokers or during later stages of prostate tumorigenesis. The latter issues remain unresolved at this time. With respect to vitamin A (retinol), some recent analyses also suggest a positive association between serologic status and prostate cancer. To this end, a pooled analysis of nested case-control serologic study data of prostate cancer within the Cohort Consortium is proposed in order to more definitively examine and establish any role for vitamins D, E, and A in its etiology. The association in aggressive and non-aggressive disease will be analyzed separately, and effect modification by several factors that might impact the influence of vitamin D (including physical activity, vitamin D intake, BMI, and time from blood collection to diagnosis) will be tested. Analysis of plasma/serum tocopherols (notably, alpha- and gamma-tocopherol that have been most commonly measured in previous studies) will focus particularly on effect modification by smoking status, in addition to disease aggressiveness and vitamin E supplement usage. Plasma/serum retinol status will also be examined for main effect and interaction with smoking status, and exploratory interactions among the three vitamins will be examined.


Related Publications:

Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2015)

Vitamin D-associated genetic variation and risk of breast cancer in the breast and prostate cancer cohort consortium (BPC3). (2015)

Genetic variation in the vitamin d pathway in relation to risk of prostate cancer--results from the breast and prostate cancer cohort consortium. (2013)

Genome-wide association study of circulating vitamin D levels. (2010)

Head and Neck Cancer Risk Factors and Risk Prediction Model Validation

Project Status:

Complete

Primary Investigator:

Mia Hashibe

Project Details:

View more information here.

Health Effects of Cigar, Cigarillo, Pipe, and Hookah Smoking

Project Status:

Complete

Primary Investigator:

Jyoti Malhotra

Project Details:

View more information here.

Leisure Time Physical Activity, Body Mass Index, and Risk of Death

Project Status:

Completed Project (Historical)

Investigator(s):

Steven C. Moore (moorest@mail.nih.gov), Alpa Patel (alpa.patel@cancer.org), and others

Year Initiated:

2011

Project Background:

Begun in 2011, the goal of this study is to identify risk of death and years of life lost or gained according to physical activity and BMI levels. This study has been completed and was published in 2012.

Related Publications:

Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. (2012)

Longitudinal Metabolomics Study on Pancreatic Cancer

Project Status:

Complete

Primary Investigator:

Li Jiao

Project Details:

View more information here.

Lung Cancer Calcium Intake Pooling Project

Male Breast Cancer Pooling Project

Project Status:

Completed Project (Historical)

Investigator(s):

Susan Gapstur (susan.gapstur@cancer.org), Michael Cook (cookmich@mail.nih.gov) and others

Year Initiated:

2008

Project Background:

The Male Breast Cancer Pooling Project, begun in 2008, is evaluating data from case-control studies to better understand causes of this rare cancer. Hormonal factors and multiple exposures considered include BMI, physical activity, diet, and family history of breast cancer. Other exposures studied include alcohol consumption, liver and thyroid diseases, infertility history, and occupational exposures. Future studies may involve genetic assays and more detailed pathologic and molecular characterization of the tumors.


Related Publications:

Physical Activity and Risk of Male Breast Cancer. (2015)

Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. (2015)

Tobacco and alcohol in relation to male breast cancer: an analysis of the male breast cancer pooling project consortium. (2015)

Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. (2014)

Menarche and the Risks of Incident Cancers and Mortality by Cause

Obesity and Rare Cancers

Project Status:

Completed Project (Historical)

Investigator(s):

Cari Kitahara (kitaharac@mail.nih.gov), Amy Berrington de Gonzalez (berringtona@mail.nih.gov), Peter Campbell (campbell@cancer.org), Mia Gaudet (mia.gaudet@cancer.org), Mark Purdue (purduem@mail.nih.gov), and others

Year Initiated:

2011

Project Background:

This project, including 22 prospective studies, will evaluate the relationship between anthropometric measures (e.g., height, baseline BMI, young-adult BMI, BMI change, waist and hip circumference) and the risk of four relatively uncommon malignancies: cancers of the thyroid, gallbladder, head/neck, and kidney. Analyses are currently underway.

Related Publications:

Body Size Indicators and Risk of Gallbladder Cancer: Pooled Analysis of Individual-Level Data from 19 Prospective Cohort Studies. (2017)

Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. (2016)

Anthropometry and head and neck cancer:a pooled analysis of cohort data. (2015)

Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. (2012)

Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. (2012)

Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. (2011)

One-Carbon Metabolism Biomarkers and Risk of Colorectal Cancer: A Pooled Analysis of Cohorts

Project Status:

Completed Project (Historical)

Investigator(s):

Paolo Vineis (p.vineis@imperial.ac.uk) and Su-Chun Chuang (s-c.chuang@imperial.ac.uk)

Year Initiated:

2011

Project Background:

This project began in 2011 to characterize folate, particularly unmetabolized folic acid, and its association with colorectal cancer. The study will explore folate status in different populations, the dose-response relationship between plasma folate and colorectal cancer and assess the effects by demographic, lifestyle, and genetic factors. By pooling data from several NCI cohorts, the project expects to improve comparability among the blood measurements in different cohorts and provide scientific evidence to inform policies on folic acid fortification.

Related Publications:

Quantifying the dose-response relationship between circulating folate concentrations and colorectal cancer in cohort studies: a meta-analysis based on a flexible meta-regression model. (2013)

One-Carbon Metabolism Pathway in Relation to the Development of Hepatocellular Carcinoma

Project Status:

Completed Project (Historical)

Investigator(s):

Jian-Min Yuan (yuanj@upmc.edu) and Lesley Butler (butlerl3@upmc.edu)

Year Initiated:

2007

Project Background:

This study, begun in 2007, assesses the association between concentrations of one-carbon metabolites in pre-diagnostic blood and the risk of developing hepatocellular carcinoma. The study also is evaluating the modifying effect of genetic polymorphisms in the genes that are involved in one-carbon metabolites and risk of hepatocellular carcinoma. Laboratory measurements of serum one-carbon metabolism biomarkers, with statistical analyses, have been completed on all hepatocellular carcinoma cases and controls of the Shanghai Cohort Study.

Related Publications:

Urinary biomarkers of catechins and risk of hepatocellular carcinoma in the Shanghai Cohort Study. (2015)

Prediagnostic levels of serum one-carbon metabolites and risk of hepatocellular carcinoma. (2013)

Parallel and Pooled Analyses of the Current Risks from Smoking

Project Status:

Completed Project (Historical)

Investigator(s):

Michael Thun (Michael.Thun@cancer.org) and others

Year Initiated:

2010

Project Background:

With the maturation of the tobacco epidemic, the relative risk (RR) estimates associated with current and former smoking continue to change in the U.S., especially among women who began smoking in adolescence, and among former smokers who have abstained for many years. These changes have implications for both estimates of the disease burden attributable to smoking and for our understanding of the etiologic contribution of current and historical smoking patterns to various disease endpoints. Currently, the statistical program used by the CDC to estimate the number of deaths attributable to smoking in the U.S. [called “Smoking Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)] is based on RR estimates for 18 chronic diseases derived from the first six years of follow-up (1982-88) of the American Cancer Society’s Cancer Prevention Study II (CPS-II). Although the CPS-II mortality cohort continues to be followed, the information on smoking status has not been updated since baseline, and analyses based on the early follow-up do not reflect likely changes in risk associated with continued smoking over the last 25 years. Furthermore, the estimates consider only mortality, not incidence, and do not take into account possible variation across racial/ethnic or socioeconomic subgroups. The latter may be most relevant, since smoking has become uncommon in higher socioeconomic groups. Ideally, the CDC Office of Smoking and Health would like to update the RR estimates for all 18 smoking related diseases considered in SAMMEC, which include ten sites or categories of cancer. The current proposal is limited to the five most common smoking-related conditions (lung cancer, ischemic heart disease, other heart disease, stroke, and COPD) that comprise the largest fraction of smoking-attributable deaths. The extent to which this collaboration will present pooled data on other smoking-related cancers must be negotiated among the participating cohorts.

Pooled Analysis of Active Smoking and Breast Cancer Risk

Project Status:

Completed Project (Historical)

Investigator(s):

Mia M. Gaudet (mia.gaudet@cancer.org)

Year Initiated:

2011

Project Background:

The Pooled Analysis of Active Smoking and Breast Cancer Risk began in 2012 to address remaining inconsistencies in key methodological issues in individual studies of the relationship between active cigarette smoking and breast cancer, by analyzing pooled data from prospective cohort studies. The factors studied will include smoking duration, alcohol consumption, mammographic screening, age at menopause, BMI, socioeconomic status, reproductive patterns, and use of postmenopausal hormones, and family history of breast cancer.


Related Publications:

Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies. (2017)

Pooled Analysis of Circulating Carotenoids and Breast Cancer Risk

Pooled Analysis of Multiple Myeloma Mortality in Relation to Anthropometric Characteristics

Project Status:

Completed Project (Historical)

Investigator(s):

Lauren Teras (lauren.teras@cancer.org), Mark Purdue (purduem@mail.nih.gov), and Cari Kitahara (meinholdc@mail.nih.gov)

Year Initiated:

2014

Project Background:

This study leveraged the collaboration network of the Multiple Myeloma Cohort Consortium (MMCC) and harmonized data resources of the BMI All-Cause Mortality Pooling Project to examine association of anthropometric measures with multiple myeloma mortality. A collaborative manuscript on anthropometric measures and mortality from multiple myeloma was published in 2014.

Related Publications:

Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. (2014)

Pooled Analysis of Time Since Birth and Breast Cancer Subtype

Project Status:

Completed Project (Historical)

Investigator(s):

Hazel B. Nichols (hazel.nichols@unc.edu)

Year Initiated:

2013

Project Background:

This project, begun in 2013, pools data from prospective studies to evaluate time since birth and breast cancer risk according to tumor subtypes and pregnancy characteristics, including age and breastfeeding history. The study evaluates whether short-term increases in breast cancer risk after pregnancy are influenced by post-partum behaviors. (This study is conducted jointly with the Pooled Analysis of Risk Factors for Premenopausal Breast Cancer.)

Prediagnositic androgens and IGF-I and risk of ovarian cancer

Risk factors for acute myeloid leukemia and myelodysplastic syndromes

Project Status:

Complete

Primary Investigator:

Jenny Poynter

Project Details:

View more information here.

Vitamin D Pooling Project of Rarer Cancers

Project Status:

Completed Project (Historical)

Investigator(s):

Kathy Helzlsouer, Stephanie Weinstein (weinstes@mail.nih.gov), Nonye Harvey (harveyn@mail.nih.gov), and others

Year Initiated:

2007

Project Background:

This project, initiated in 2007, is a nested case-control study that analyzed the association between 25(OH)D (serum vitamin D concentrations) and the development of seven rarer cancers: endometrial, esophageal, stomach, ovarian, pancreatic, and kidney cancers, and non-Hodgkin lymphoma (NHL). The study involved 10 cohorts, and participants' vitamin D levels were measured in serum collected before the development of cancer. Study findings do not support the hypothesis that circulating 25(OH) D concentrations are associated with a reduced risk of developing any of these seven rarer cancers. The results were published in 2010. For more information, please visit: https://epi.grants.cancer.gov/vitamind/

Related Publications:

Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)

Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. (2010)